Swiss pharma giant Roche said it plans to cut 4,800 jobs worldwide over the next two years due to mounting cost pressures in healthcare -particularly in the US and Europe - and increasing hurdles for the approval and pricing of new medicines.
The United States National Institutes of Health said on Thursday it will share intellectual property rights on some AIDS drugs in a patent pool designed to make treatments more widely available to the poor.
A new blood-thinning drug moved closer to U.S. approval on Monday, leading a pack of stroke-fighting medicines vying to compete in an estimated $10 billion a year market.
Drugmaker Wyeth used ghostwriters to play up the benefits and downplay the harm of hormone replacement therapy in articles published in medical journals, U.S. researchers said on Tuesday.
Wall Street was set to close out its best week in six on Friday after recent economic data, including a stronger-than-expected jobs report, showed the U.S. economy may be in better shape than thought.
Wall Street advanced for a third day on Friday as the monthly payrolls data showed the U.S. economy may be in better shape than investors had thought and helped whet some investor appetite for risk.
Wall Street was poised for a strong open on Friday after a better-than-expected jobs report lifted investor optimism on the economy.
The Obama administration will spend $5 billion to reimburse 80 percent of the companies' health insurance costs provided to early retirees who leave the US workforce between the ages of 55 to 64.
An experimental drug from Bristol-Myers Squibb and Pfizer reduces the risk of stroke by more than half compared with aspirin, with no significant rise in major bleeding, researchers said on Tuesday.
An international scientific team has identified for the first time a genetic risk factor associated with common migraines and say their research could open the way for new treatments to prevent migraine attacks.
Cutting medicine prices and promoting cheap generics in the way European governments are now doing could jeopardize the long-term supply of new heart drugs, a top cardiologist said on Saturday.
A rare and dangerous reaction to a range of common medicines including antibiotics and anticonvulsants may be caused by a severe immune response to reactivated herpes virus, scientists said on Wednesday.
Australia's drug modulator has revealed 15 people have committed suicide and hundreds have experienced suicidal thoughts while on Champix - the popular smoking-cessation drug, since 2008.
Pfizer Inc
posted higher-than-expected quarterly results and stood by its longer-term profit view, allaying investor concern over looming generic drug competition and lifting its shares almost 6 percent.Sanofi-Aventis investors have urged the drugmaker not to pay more than about $19 billion to land Genzyme, some $10 a share below the price wanted by the U.S. biotech group.
Stocks slipped on Tuesday after disappointing results from Dow component Procter & Gamble and some discouraging economic data, but robust earnings from drug giant Pfizer limited the market's decline.
Pfizer Inc
posted higher-than-expected quarterly results and stood by its longer-term profit view, allaying investor concern over looming generic drug competition and lifting its shares 5 percent.Sanofi-Aventis chief Chris Viehbacher should avoid paying much more than about $70 per share, or a total of $19 billion, to land U.S. biotech group Genzyme, shareholders in the French group say.
Sanofi-Aventis sent a takeover proposal valued at about $18.4 billion, or $69 per share, to biotechnology company Genzyme Corp and the two sides are discussing the offer, sources familiar with the situation said on Monday.
Pfizer reported higher-than-expected quarterly earnings and revenue, and the world's biggest drugmaker said its full-year profit will be at the upper end of its prior view as savings continue to pile on from its recent merger with Wyeth.
Pfizer Inc reported higher-than-expected quarterly earnings and revenue, and the world's biggest drugmaker said its full-year profit will be at top end of its prior view as savings accrue from its recent merger with Wyeth.
Drugmakers Merck, Tibotec and Gilead are in advanced talks with UNITAID about a patent pool to make AIDS drugs more widely available to the poor, the health funding agency said on Wednesday.
